Clinical Trials

Phase 3 Active not recruiting

Stomach Neoplasms

NCT04639180 2025-12-30

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

687 enrolled

Carcinoma, Hepatocellular

NCT06361888 2025-12-30

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Phase 2/3 Recruiting

502 enrolled

Pancreatic Neoplasms

NCT03813784 2025-09-16

A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy

885 enrolled

Stomach Neoplasms

NCT04680988 2025-08-05

A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer

194 enrolled

Gynecologic

Uterine Cervical Neoplasms, Recurrence

NCT03777124 2025-07-04

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

25 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05799183 2024-12-31

A SHR-1210 BE Study on Healthy Subjects

Phase 1 Terminated

12 enrolled

Advanced Tumors

NCT03417895 2024-08-07

PASSION

59 enrolled 17 charts

Phase 2/3 Not yet recruiting

Small Cell Lung Carcinoma

NCT06335355 2024-03-28

A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients

401 enrolled

Non-squamous Non-small Cell Lung Cancer

NCT04613674 2024-03-27

A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

441 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03558191 2024-03-15

SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.

156 enrolled 13 charts

Head & Neck

Nasopharyngeal Carcinoma

NCT03711279 2024-02-29

A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma

99 enrolled 10 charts

Sarcoma

NCT03764293 2024-02-06

A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC

543 enrolled 13 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT03155425 2024-02-01

PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma

75 enrolled 10 charts

Lymphoid

Hodgkin Disease

NCT03099382 2024-01-22

Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer

457 enrolled 9 charts

Esophageal Neoplasms

NCT03472365 2024-01-11

A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer

67 enrolled 12 charts

Stomach Neoplasms

NCT05576272 2023-11-22

A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma

Phase 2/3 Unknown

460 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04346381 2023-09-18

Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor

233 enrolled

Solid Tumor

NCT05841472 2023-08-30

Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Phase 2 Recruiting

60 enrolled

Non Squamous Non Small Cell Lung Cancer

NCT05106335 2023-08-16

A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC

Phase 3 Terminated

1 enrolled

Advanced NSCLC

NCT03871855 2023-06-05

A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors

Phase 1 Terminated

8 enrolled

Advanced Solid Tumor

NCT02721589 2023-02-28

A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects

126 enrolled

Advanced Solid Tumors

NCT02742935 2023-02-27

A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects

99 enrolled

BreastGastrointestinal

Breast Neoplasms, Gastrointestinal Neoplasms

NCT05214976 2022-12-22

A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients

Phase 2 Unknown

64 enrolled

Advanced Solid Tumors

NCT05042375 2022-11-17

A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

Phase 3 Unknown

450 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03182673 2022-09-01

The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors

Phase 1 Terminated

31 enrolled

Solid Tumor

NCT03945604 2022-08-12

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

32 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03121716 2022-07-12

A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects

23 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT03827837 2022-07-01

Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors

Phase 2 Unknown

265 enrolled

GenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Endometrial Neoplasms

NCT04426955 2021-09-16

Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer

Phase 3 Unknown

396 enrolled

Esophageal Neoplasms

NCT03666728 2021-03-17

A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC

5 enrolled

Lung Neoplasms

NCT03363555 2020-06-18

SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma

Phase 2 Unknown

97 enrolled

Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT04203485 2020-05-08

Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 3 Unknown

762 enrolled

PD-L1 Positive Non-small Cell Lung Cancer

NCT02492789 2019-09-30

A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients

Other hematologic neoplasm

49 enrolled

Hematologic Neoplasms

NCT03393416 2019-08-29

A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild Tumor

Phase 1 Unknown

28 enrolled

Advanced Gastric Cancer

NCT03645876 2019-05-10

SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer

12 enrolled